Cancer Immunology, Immunotherapy

Published by: Springer  

People

  1. Ragupathi
    Ragupathi
  2. Jungbluth
    Jungbluth
  3. Cheung
    Cheung
  4. Danishefsky
    Danishefsky
  5. Scheinberg
    Scheinberg
  6. Sadelain
    Sadelain
  7. Wolchok
    Wolchok
  8. Adusumilli
    Adusumilli
  9. Dao
    Dao
  10. Korontsvit
    Korontsvit

Groups

  1. Department of Medicine (35)
  2. Solid Tumor Oncology Division (26)
  3. Melanoma and Immunotherapeutics Service (20)
  4. GSK Faculty (15)
  5. Sloan Kettering Institute Faculty (14)
  6. Hematologic Malignancies, Division of (13)
  7. Molecular Pharmacology and Chemistry Program Faculty (11)
  8. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (9)
  9. Sloan Kettering Institute Postdocs (9)
  10. Center for Hematologic Malignancies (8)
Search Within
Formats
  1. Journal Article (76)
  2. Editorial (1)
Groups
  1. Department of Medicine (35)
  2. Solid Tumor Oncology Division (26)
  3. Melanoma and Immunotherapeutics Service (20)
  4. GSK Faculty (15)
  5. Sloan Kettering Institute Faculty (14)
  6. Hematologic Malignancies, Division of (13)

More Groups

People
  1. Philip Livingston (18)
  2. Govindaswami Ragupathi (15)
  3. Kenneth Lloyd (6)
  4. Lloyd Old (6)
  5. Achim Jungbluth (5)
  6. Gerd Ritter (5)

More People

Years
  1. 2023 (2)
  2. 2022 (2)
  3. 2021 (3)
  4. 2020 (1)
  5. 2019 (2)
  6. 2018 (1)

More Years

Publishers
  1. Springer (77)

Results (77)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: A propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival
    Journal Article

    Weber, J. S.; Poretta, T.; Stwalley, B. D.; Sakkal, L. A.; Du, E. X.; Wang, T.; Chen, Y.; Wang, Y.; Betts, K. A.; Shoushtari, A. N.
    Cancer Immunology, Immunotherapy (2023)

    Fulltext@MSK | Save
  • Long-term outcomes of patients with recurrent ovarian cancer treated with a polyvalent vaccine with bevacizumab combination
    Journal Article

    Kahn, R. M.; Ragupathi, G.; Zhou, Q. C.; Iasonos, A.; Kravetz, S.; Hensley, M. L.; Konner, J. A.; Makker, V.; Tew, W. P.; Aghajanian, C.; more...
    Cancer Immunology, Immunotherapy (2023)

    Fulltext@MSK | Save
  • Serial interferon-gamma release assay in lung cancer patients receiving immune checkpoint inhibitors: A prospective cohort study
    Journal Article

    Fujita, K.; Elkington, P.; Redelman-Sidi, G.; Kanai, O.; Yamamoto, Y.; Imakita, T.; Okamura, M.; Nakatani, K.; Mio, T.
    Cancer Immunology, Immunotherapy (2022)

    Fulltext@MSK | Save
  • Murine fecal microbiota transfer models selectively colonize human microbes and reveal transcriptional programs associated with response to neoadjuvant checkpoint inhibitors
    Journal Article

    Shaikh, F. Y.; Gills, J. J.; Mohammad, F.; White, J. R.; Stevens, C. M.; Ding, H.; Fu, J.; Tam, A.; Blosser, R. L.; Domingue, J. C.; more...
    Cancer Immunology, Immunotherapy (2022)

    Fulltext@MSK | Save
  • Platelet-expressed immune checkpoint regulator GITRL in breast cancer
    Journal Article

    Zhou, Y.; Heitmann, J. S.; Clar, K. L.; Kropp, K. N.; Hinterleitner, M.; Engler, T.; Koch, A.; Hartkopf, A. D.; Zender, L.; Salih, H. R.; more...
    Cancer Immunology, Immunotherapy (2021)

    Fulltext@MSK | Save
  • Mast cell proliferation in the cerebrospinal fluid after intraventricular administration of anti-B7H3 immunotherapy
    Journal Article

    Kramer, K.; Donzelli, M. A.; Pessin, M. S.
    Cancer Immunology, Immunotherapy (2021)

    Fulltext@MSK | Save
  • Impact of tumor heterogeneity and microenvironment in identifying neoantigens in a patient with ovarian cancer
    Journal Article

    Dao, T.; Klatt, M. G.; Korontsvit, T.; Mun, S. S.; Guzman, S.; Mattar, M.; Zivanovic, O.; Kyi, C. K.; Socci, N. D.; O’Cearbhaill, R. E.; more...
    Cancer Immunology, Immunotherapy (2021)

    Fulltext@MSK | Save
  • Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: A pooled exploratory analysis from a global cohort
    Journal Article

    Naqash, A. R.; Ricciuti, B.; Owen, D. H.; Florou, V.; Toi, Y.; Cherry, C.; Hafiz, M.; De Giglio, A.; Muzaffar, M.; Patel, S. H.; more...
    Cancer Immunology, Immunotherapy (2020)

    Fulltext@MSK | Save
  • Early objective response to avelumab treatment is associated with improved overall survival in patients with metastatic Merkel cell carcinoma
    Journal Article

    D’Angelo, S. P.; Hunger, M.; Brohl, A. S.; Nghiem, P.; Bhatia, S.; Hamid, O.; Mehnert, J. M.; Terheyden, P.; Shih, K. C.; Brownell, I.; more...
    Cancer Immunology, Immunotherapy (2019)

    Fulltext@MSK | Save
  • Addressing current challenges and future directions in immuno-oncology: Expert perspectives from the 2017 NIBIT Foundation Think Tank, Siena, Italy
    Editorial

    Maio, M.; Coukos, G.; Ferrone, S.; Fox, B. A.; Fridman, W. H.; Garcia, P. L.; Lahn, M.; Provendier, O.; Russo, V.; Rüttinger, D.; more...
    Cancer Immunology, Immunotherapy (2019)

    Fulltext@MSK | Save

    • Cancer Immunology, Immunotherapy – authorized name for:

    Name ISSN / ISBN Publisher
    Cancer Immunology and Immunotherapy 978-3-642-14136-2 Springer Verlag
    Cancer Immunology Immunotherapy 0340-7004 Springer
    Cancer Immunology Immunotherapy 0340-7004 Unknown
    Cancer Immunology Immunotherapy 0340-7004 Springer
    Cancer Immunology Immunotherapy 0340-7004 Springer
    Cancer Immunology Immunotherapy 0340-7004 Springer Verlag
    Cancer Immunology Immunotherapy 03407004 Springer Verlag
    Cancer Immunology Immunotherapy 03407004 Unknown
    Cancer Immunology Immunotherapy 0340-7004 Springer Verlag
    Cancer Immunology, Immunotherapy 0340-7004 Springer Verlag
    Cancer Immunology, Immunotherapy 0340-7004 Springer Verlag
    Cancer Immunology, Immunotherapy 0340-7004 Springer
    Cancer Immunology, Immunotherapy 0340-7004 Springer
    Cancer Immunology, Immunotherapy 03407004 Springer Verlag
    Cancer Immunology, Immunotherapy 0340-7004 Springer
    Cancer Immunology, Immunotherapy 03407004 2022, The Author(s), Under Exclusive Licence To Springer Verlag Gmbh Germany, Part of Springer Nature
    Cancer Immunology, Immunotherapy 03407004 Springer Verlag
    Cancer Immunology, Immunotherapy 03407004 Springer Verlag
    Cancer Immunology, Immunotherapy 03407004 2018, Springer Verlag Gmbh Germany, Part of Springer Nature
    Cancer Immunology, Immunotherapy 03407004 2019, The Author(s)
    Cancer Immunology, Immunotherapy 03407004 Springer Verlag
    Cancer Immunology, Immunotherapy 03407004 The Author(s)
    Cancer Immunology, Immunotherapy 03407004 2022, The Author(s)
    Cancer Immunology, Immunotherapy 03407004 Springer Verlag
    Cancer Immunology, Immunotherapy 03407004 Springer Verlag Berlin Heidelberg
    Cancer Immunology, Immunotherapy 03407004 Springer Verlag Berlin Heidelberg
    Cancer Immunology, Immunotherapy 0340-7004 Springer
    Cancer Immunology, Immunotherapy 03407004 Springer Verlag
    Cancer Immunology, Immunotherapy 0340-7004 Springer
    Cancer Immunology, Immunotherapy 0340-7004 Springer
    Cancer Immunology, Immunotherapy 03407004 Unknown
    Cancer Immunology, Immunotherapy 03407004 Us Government